Author

D. Hammond

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:clinical cohort / trial· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

S. Loghavi· 2 shared A. C. Jain· 1 shared A. Malovannaya· 1 shared B. Cuglievan· 1 shared C. D. DiNardo· 1 shared C. E. Birdwell· 1 shared C. P. Mill· 1 shared F. Ma· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. Loghavi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

W. C. Fiskus, J. Piel, M. Collins, M. Hentemann, B. Cuglievan, C. P. Mill, C. E. Birdwell, K. Das, J. A. Davis, H. Hou, A. C. Jain, A. Malovannaya, T. M. Kadia, N. Daver, K. Sasaki, , K. N. Bhalla

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

bioRxiv · Sep 28, 2023Cancer Biology

IL-1B-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes

V. Adema, I. Ganan-Gomez, F. Ma, J. J. Rodriguez-Sevilla, K. Chien, H. Yang, N. Thongon, R. Kanagal-Shamanna, S. Loghavi, G. Montalban-Bravo, D. Hammond, Y. Gu, R. Tan, L. Tan, P. Lorenzi, , S. Colla

This study shows that IL-1B-mediated inflammation drives ineffective erythropoiesis in early-stage MDS and that canakinumab can reduce transfusion dependence in patients with DNMT3A and TET2 mutations.

bioRxiv · Sep 28, 2023 · PreprintCancer Biology